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Dedifferentiated vascular smooth muscle cells (VSMCs) are phenotypically modulated from the contractile state to the active
synthetic state in the vessel wall. In this study, we investigated the effects of resveratrol on phenotypemodulation by dedifferentiation
and the intracellular signal transduction pathways of platelet derived growth factor-bb (PDGF-bb) in rat aortic vascular smooth
muscle cells (RAOSMCs). Treatment of RAOSMCs with resveratrol showed dose-dependent inhibition of PDGF-bb-stimulated
proliferation. Resveratrol treatment inhibited this phenotype change and disassembly of actin filaments and maintained the
expression of contractile phenotype-related proteins such as calponin and smooth muscle actin-alpha in comparison with only
PDGF-bb stimulated RAOSMC. Although PDGF stimulation elicited strong and detectable Akt and mTOR phosphorylations
lasting for several hours, Akt activation was much weaker when PDGF was used with resveratrol. In contrast, resveratrol only
slightly inhibited phosphorylations of 42/44 MAPK and p38 MAPK. In conclusion, RAOSMC dedifferentiation, phenotype, and
proliferation rate were inhibited by resveratrol via interruption of the balance of Akt, 42/44MAPK, and p38MAPK pathway
activation stimulated by PDGF-bb.
1. Introduction
Vascular smooth muscle cells (VSMC) exhibit differentiated,
biosynthetic, contractile roles in the media layer of mature
blood vessels. However, VSMC dedifferentiation is induced
in response to injury in a vessel, followed by phenotypic
modulation toward a proliferative, migratory, and synthetic
phenotype with extracellular matrix protein deposition,
which contributes to intimal hyperplasia [1–3]. Differentiated
VSMCs in normal vessels have a contractile phenotype, a
spindle-like elongated morphology, and a smaller cell size.
In contrast, dedifferentiated VSMCs in injured vessels have
a synthetic phenotype, a hypertrophic appearance, hill and
valley growth, and a relatively larger size. In addition to
thesemorphological and functional alterations, the change in
VSMCs from contractile to synthetic phenotype is controlled
by SMC-specific molecular markers such as caldesmon,
calponin, alpha-tropomysin, smooth muscle myosin heavy
chain, SM22𝛼, and smoothmuscle alpha actin (𝛼SMA) [4–6].
Platelet derived growth factor-bb (PDGF-bb) is one of
the most potent mitogens and chemoattractants for VSMCs.
PDGF-bb binds to the PDGF receptor (PDGFR)-𝛽 and
utilizes the tyrosine kinase receptor signaling leading to gen-
eration of reactive oxygen species (ROS) and subsequently
activates several intracellular signaling cascades, including
the extracellular signal-regulated kinase (ERK) and p38
mitogen-activated protein kinase (MAPK) pathways and the
phosphatidylinositol 3-kinase-Akt (PI3K-Akt) pathway. It has
also been shown to stimulate VSMC dedifferentiation [7–
9]. Akt is the major signal transducer in growth factor-
mediated transcription and promotes cell survival by inhibit-
ing apoptosis. Furthermore, theAkt pathway is the key trigger
of mTOR signaling, and Akt-mediated phosphorylation is
directly related to mTOR activation. The mTOR protein has
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been implicated in cardiovascular diseases and specifically in
cardiac hypertrophy [10, 11].
Resveratrol (3,4󸀠,5-trihydroxystilbene), a naturally occur-
ring molecule known as a phytoalexin, is a polyphonic
compound found in grapes and red wine. Resveratrol
is also known to possess antioxidant, anti-inflammatory,
antithrombotic, and antiproliferative effects. Additionally,
various studies have shown that resveratrol inhibits the
oxidation of low-density lipoprotein (oxLDL) and the early
progression of atherosclerotic lesions and also protects car-
diomyocytes against ischemia-reperfusion injury [12–14].
Although numerous studies have addressed the effects of red
wine consumption on cardioprotection, alcohol contained
in red wine interacts with resveratrol to elicit the desired
effects. For that reason, several studies have demonstrated
that both resveratrol supplement and dealcoholized red wine
have physiological activity for cardiovascular protection [15,
16].
In this study, we investigated the effects of resveratrol
on proliferation, phenotype modulation, and intracellular
signal transduction pathways in PDGF-bb-induced rat aor-
tic vascular smooth muscle cells (RAOSMCs). Our results
demonstrate the inhibitory mechanism of resveratrol on
phenotype modulation of PDGF-bb-stimulated RAOSMCs.
2. Materials and Methods
2.1. Cell Culture. Primary cultured rat aortic smooth mus-
cle cells (RAOSMCs, Biobud, Seoul, Korea) were routinely
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
(Gibco, Carlsbad, CA, USA) supplemented with 10% fetal
bovine serum (Sigma, St. Louis, MO, USA) and a 1%
antibiotic-antimycotic solution containing 10,000 units peni-
cillin, 10mg streptomycin, and 25 𝜇g/mL amphotericin B
(Sigma) at 37∘C in a humidified atmosphere of 5% CO
2
. For
experiments, cells were used between passages 5 and 10.
2.2. Cell Stimulation by PDGF-bb and Treatment of Resver-
atrol. RAOSMCs were grown to 80–90% confluence and
synchronized in serum-free DMEM medium for 48 h before
experiments. Trans-resveratrol (Sigma) was dissolved in 50%
dimethylsulphoxide (DMSO) (Sigma) for a stock solution
of 100mM and then diluted to desired concentrations with
media prior to cell treatment. Cells were treated with various
concentrations of resveratrol: 10∼200𝜇M in cell proliferation
assay, 20 𝜇M in cell morphology analysis, and 100 𝜇M in
western blotting on quiescent cells with or without 10 ng/mL
PDGF-bb for designated times.
2.3. Cell Proliferation and DNA Synthesis. Cell viabil-
ity was determined by MTT assay [reduction of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to a
purple formazan product, Sigma]. For the MTT assay, cells
were incubated with 0.5mg/mL MTT in the last 4 h of the
culture period and tested at 37∘C in the dark. The media
were decanted, the produced formazan salts were dissolved
in DMSO, and the absorbance was determined at 570 nm by
an automatic microplate reader (Spectra Max 340, Molecular
Devices Co., Sunnyvale, CA, USA). DNA synthesis was per-
formed by a 5-bromo-2󸀠-deoxyuridine (BrdU) incorporation
assay (Roche Applied Science, Seoul, Korea). Briefly, BrdU-
labeling solution was added to the cells, and cells were incu-
bated for 2 h at 37∘C.The labelingmediumwas then removed,
and cells were incubated with fixation solution for 30min
at room temperature. After fixation of the cells, anti-BrdU-
POD working solution was added, and cells were incubated
for 90min at room temperature. Then, the substrate solution
was added, and the absorbance was measured at 370 nm with
a 492 nm reference wavelength by an automatic microplate
reader (Spectra Max 340, Molecular Devices Co.).
2.4. Immunofluorescence Assay. Cells were grown on cov-
erslips to 50% confluence, serum-starved for 48 h, and
then stimulated with or without 10 ng/mL PDGF-bb and
10 or 20𝜇M resveratrol. Stimulated cells were fixed in 10%
formalin solution and permeabilized with 0.5% Triton X-
100 in phosphate buffer saline (PBS, pH 7.6). Then, cells
were blocked with 5% bovine serum albumin (BSA, Sigma)
and incubated with anti-smooth muscle actin-𝛼 (𝛼SMA,
Dako North America Inc., CA, USA) and anti-calponin
(Santa Cruz Biotechnology Inc., Sana Cruz, CA, USA). Cells
were then incubated with the secondary antibody, goat-
anti-mouse IgG-conjugated Texas Red (Santa Cruz). Alexa
488-conjugated rhodamine phalloidin (5U/mL, Invitrogen,
Carlsbad, CA, USA) was used to visualize F-actin stress
fibers, and nuclei were stained with Hoechst 33528. Cover-
slips were mounted with aqueous mounting medium (Dako
Faramount, Dako North America Inc.), and images were
evaluated using fluorescence microscope (Olympus, Tokyo,
Japan) equipped with a DP-71 digital camera (Olympus).
2.5. Morphology Analysis. For morphology analysis, a cell
plasma membrane was visualized by staining it with Texas
Red C2-maleimide (5U/mL, Invitrogen) and Hoechst 33258
(1 𝜇g/mL in PBS, Sigma). Images were captured on a fluores-
cence microscope (Olympus) equipped with a DP-71 digital
camera (Olympus). Cell circularity and an area of 100 cells
for each group were analyzed using ImageJ software (NIH,
Bethesda, MD, USA). The circularity was measured to deter-
mine the morphological distribution between the contrac-
tile phenotype and the synthetic phenotype of RAOSMCs.
Circularity was presented from 0 to 1, with values closer
to 0 indicating spindle morphology and those closer to 1
indicating a circular phenotype [17, 18].
2.6. Western Blotting. After time-course stimulation with
PDGF-bb, the cells were washed twice with cold PBS (10mM,
pH 7.4). Ice-cold RIPA lysis buffer (Santa Cruz Biotechnol-
ogy) was added to the cells for 5min. The cells were scraped,
and the lysate was cleared by centrifugation at 14,000×g for
20min at 4∘C.The resultant supernatant (total cell lysate) was
collected. The protein concentration was determined using
a DC Bio-Rad assay kit (Bio-Rad Laboratories, Hercules,
California, USA). For immunoblot analysis, proteins were
separated by 10–15% SDS-PAGE and then electrotransferred
onto a PVDF membrane. The membrane was blocked with
Oxidative Medicine and Cellular Longevity 3
blocking buffer (5% bovine serum albumin and 1% Tween-20
in 20mM TBS, pH 7.6) for 1 h at room temperature and then
probed overnight with antibodies to phospho-PDGFR-𝛽
(p-PDGFR-𝛽, Tyr751), total PDGFR-𝛽, phospho-MEK1/2 (p-
MEK1/2, Ser217/221), total MEK1/2, phospho-p42/44MAPK
(p-p42/44MAPK, Thr202/Tyr204), total p42/44MAPK,
phospho-Akt (p-Akt, Ser473), total Akt, phospho-mTOR
(p-mTOR, Ser2448), total mTOR, phospho-p38 MAPK (p-
p38MAPK,Thr180/Tyr182), and total p38MAPK. Antibodies
were purchased from Cell Signaling Technology (Danvers,
MA, USA) and used at 1 : 1,000 dilutions. Detection of
horseradish peroxidase-conjugated secondary antibody (i.e.,
anti-rabbit IgG (1 : 2,000) and antimouse IgG (1 : 2,000) from
Santa Cruz Biotechnology Inc.) was accomplished using
enhanced chemiluminescence of the ECL Plus detection
kit (Amersham Biosciences, Buckinghamshire, England).
The band intensity was quantified using ImageJ software
(NIH) and relative fold exchanges averaged across the three
experiments (normalized to phosphorylated forms and total
forms) are shown below each band.
2.7. Statistical Analysis. All variables were tested in three
independent cultures for each experiment. The results are
reported as mean ± SD compared to nontreated controls.
Statistical analysis was performed using a one-way ANOVA,
followed by a Tukey’s HSD test for multiple comparisons
using SPSS software. A 𝑃 value < 0.05 was considered
statistically significant.
3. Results
3.1. Inhibitory Effect of Resveratrol on PDGF-bb-Induced Pro-
liferation in RAOSMCs. To assess whether resveratrol inhib-
ited PDGF-bb-stimulated RAOSMC proliferation, serum-
starved RAOSMCs were incubated with 10 ng/mL PDGF-
bb and increasing concentrations of resveratrol for 48 h.
Treatment with 10 ng/mL PDGF-bb induced proliferation of
RAOSMCs in comparison with nonstimulated cells. How-
ever, the presence of resveratrol resulted in significant (𝑃 <
0.05) dose-dependent decreases in cell growth (Figure 1(a)).
When cells were treated with increasing concentrations of
resveratrol, a significant (𝑃 < 0.05) dose-dependent reduc-
tion in cell growth was observed starting at 50 𝜇M.The level
of DNA synthesis was also measured by cell proliferation
assay. Stimulation of RAOSMCs with 10 ng/mL PDGF-bb
caused a significant increase in the DNA amount, and resver-
atrol significantly inhibited this increase in a concentration-
dependent manner (Figure 1(b)). Furthermore, increases
in cell viability and DNA synthesis induced by PDGF-bb
stimulation were completely suppressed in cells treated with
concentrations of resveratrol greater than 100 𝜇M. These
results suggest that resveratrol exerts a potent antiprolifera-
tive effect on PDGF-bb-stimulated RAOSMC proliferation.
3.2. Inhibitory Effect of Resveratrol on PDGF-bb-Stimulated
RAOSMC Morphology and Phenotype. To define pheno-
type exchange in PDGF stimulation, we assessed RAOSMC
phenotype and morphology using immunofluorescence and
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Figure 1: Antiproliferative activity of resveratrol in PDGF-bb-
stimulated RAOSMCs. After 24 h of starvation with serum-free
DMEM, cells were treated with 10 ng/mL PDGF-bb and increasing
concentrations (10–200𝜇M) of resveratrol for 48 h. (a) The effect of
resveratrol growth inhibition on PDGF-bb-stimulated RAOSMCs.
Cell viability was detected using the MTT assay. (b) The effect
of resveratrol on PDGF-bb-induced DNA synthesis in RAOSMCs.
DNA synthesis was detected using the BrdU incorporation assay.
∗
𝑃 < 0.05 compared with nonstimulated controls; #𝑃 < 0.05
compared with 10 ng/mL PDGF-bb-stimulated controls.
immunocytochemical stainingwith antibodies against𝛼SMA
and calponin. RAOSMCs were grown on glass cover slips,
starved of serum for 48 h, and stimulated in the presence and
absence of PDGF-bb and resveratrol for 24 h.
RAOSMCs exhibited elongation and spindlemorphology
during prolonged serum deprivation. As shown in Figure 2,
RAOSMCs serum-starved for 48 hr revealed an aligned
arrangement of actin filaments with an organized cytoskele-
ton network. In contrast, PDGF-bb-stimulated RAOSMCs
showed disassembled distribution and aggregation around
the perinuclear region of actin filaments without clear fil-
amentous organization. However, RAOSMCs treated with
resveratrol maintained spindle-like shapes and organization
of the actin filaments by inhibiting the effects of PDGF-bb-
stimulation.
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Figure 2: Arrangement of F-actin filaments of RAOSMCs with or without 10 ng/mL PDGF-bb stimulation and 20 𝜇M resveratrol. Nuclei
were stained blue with Hoechst 33528, and F-actin was green due to alexa (388)-rhodamine phalloidin. Images in the upper and low panels
were obtained at ×400 and ×1000 original magnifications, respectively. The micrographs shown in this figure are representative of three
independent experiments with similar results.
Therefore, cells were examined for accumulation of
the contractile-related proteins, 𝛼SMA (Figure 3(a)) and
calponin (Figure 3(d)), in clear actin filament organization.
When RAOSMCs were stimulated with PDGF-bb, cells were
observed to undergo morphological changes from spindle-
shaped to polygonal, and relatively low levels of 𝛼SMA
(Figure 3(b)) and calponin were noted (Figure 3(e)) with dis-
assembled distribution of actin filaments in the cytosol. How-
ever, treatment with 20𝜇Mresveratrol inhibited themorpho-
logical changes. Furthermore, when cells were treated with
resveratrol, the actin cytoskeleton maintained parallel actin
filaments by forming a complex with contractile phenotype-
related proteins, including 𝛼SMA (Figure 3(c)) and calponin
(Figure 3(f)). To determine the morphological distribution
of the cells, circularity was measured by ImageJ analysis.
Compared to serum-starved cells, PDGF-bb-stimulated cells
showed a greater distribution in circularity, whereas cells
treated with resveratrol exhibited lower circularity (Fig-
ure 4(a)). The average circularity of PDGF-bb-stimulated
cells was significantly higher than that of nontreated cells.
However, resveratrol-treated cells stimulated with PDGF-
bb were not significantly different from the nontreated cells
(Figure 4(b)). Therefore, PDGF-bb-stimulated RAOSMCs
had a greater area compared with serum-starved RAOSMCs.
Resveratrol inhibited the change in area stimulated by PDGF-
bb (Figure 4(c)).
3.3. Inhibitory Mechanism of Dedifferentiation on PDGF-
bb-Stimulated RAOSMCs by Resveratrol. Treatment of
RAOSMCs with resveratrol significantly inhibited PDGF-
bb-stimulated proliferation in a dose-dependent manner.
Furthermore, treatment of cells with 100 𝜇M resveratrol
almost completely inhibited the growth of ROASMCs, as
shown by DNA synthesis assay and MTT assay.
To define the effects of resveratrol on signaling pathways
involved in PDGF-bb-stimulated dedifferentiation, serum-
starved cells were stimulated with 10 ng/mL PDGF-bb in the
absence or presence of resveratrol for specified times. Then,
we analyzed the activation of p42/44MAPK, p38MAPK, and
Akt, downstream effectors of PDGF-bb-induced signaling, by
Western blotting.
Addition of 10 ng/mL PDGF-bb to serum-starved cells
led to PDGFR-𝛽 phosphorylation that peaked within 10min
of stimulation and returnedto baseline level after 2∼4 h,
with similar results achieved in atleast three independent
experiments (Figure 5(a)). However, resveratrol treatment
inhibited PDGFR-𝛽 phosphorylation induced byPDGF-bb at
only 10min, while no inhibition of PDGFR-𝛽 phosphoryla-
tion was observed during incubations longer than 30min.
In a similar manner, PDGF-bb stimulated the phos-
phorylations of downstream effectors such as MEK1/2,
p42/44MAPK (Figure 5(b)), and p38 (Figure 5(c)), and
resveratrol only slightly inhibited the PDGF-bb-induced
phosphorylations of MEK1/2, p42/44MAPK, and p38MAPK
in a time-dependent manner. However, as shown in Fig-
ure 5(d), while PDGF stimulation elicited strong and
detectable signals for Akt and mTOR phosphorylations for
several hours, resveratrol treatment clearly inhibited the
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Figure 3: Characterization ofmorphologymodulation by resveratrol on PDGF-bb-stimulatedRAOSMCs. Cells were incubated in serum-free
media (a, d), 10 ng/mL PDGF-bb (b, e), or 20 𝜇M resveratrol with 10 ng/mL PDGF-bb (c, f). Nuclei were stained blue with Hoechst 33528,
𝛼SMA (a∼c) and calponin (d∼f) are red, and F-actin is green due to alexa (388)-rhodamine phalloidin. The micrographs (magnification,
×100) shown in this figure are representative of three independent experiments with similar results.
PDGF-mediated phosphorylations of Akt and mTOR, a
downstream effector dependent on Akt.
4. Discussion
Changes of the differentiated VSMC play a critical role
in cardiovascular diseases, such as atherosclerosis, hyper-
tension, asthma, and vascular aneurisms. Identification of
dedifferentiated VSMCs was based onmorphological criteria
that met the terms for “phenotypic modulation” or “pheno-
typic switching” in functional and structural properties. A
phenotypic switch from a contractile to synthetic phenotype
accompanies the proliferation and migration of cells [19, 20].
PDGF, a key mediator in the proliferation of VSMCs,
plays an important role in the pathogenesis of various
vascular disorders. It has already been reported that PDGF-
bb is implicated in intracellular ROS generation and VSMC
growth [7, 21]. Furthermore, the signaling pathways affected
by PDGF are so similar to that activated by oxidative stress
[22, 23]. PDGF-bb represses the characteristic VSMC gene
expression by activating extracellular signal-regulated kinase
1/2-mitogen activated protein kinase (ERK1/2-MAPK), p38
MAPK, and Akt pathways in cultured VSMCs [24, 25].
This study reports that PDGF-bb treatment causes phe-
notypic changes typical of dedifferentiation in RAOSMCs by
activating p42/44 MAPK, p38 MAPK, and Akt pathways.
In our experimental system, resveratrol inhibited the prolif-
eration of PDGF-bb-stimulated RAOSMCs. The contractile
morphology and spindle phenotype of the cells were also
preserved by resveratrol treatment. Therefore, markers of
VSMC differentiation, such as 𝛼SMA and calponin, were not
inhibited by resveratrol treatment. In other words, resveratrol
might prevent morphologic changes from contractile to
synthetic phenotype. VSMCs inmature animal vessels exhibit
a contractile phenotype (differentiated state) and express
multiple contractile proteins, including 𝛼SMA, SM22𝛼, and
SM-MHC [26, 27]. Calponin and 𝛼SMA are characterized in
detail as F-actin binding components of smooth muscle thin
filaments, and they control actin-based cellular processes by
regulating the stability of the actin cytoskeleton [6, 28].
The investigation of signal transduction pathways
induced by PDGF-bb showed that resveratrol can inhibit
phosphorylation of PDGFR-𝛽, 42/44 MAPK, Akt, and
p38MAPK. In particular, Akt/mTOR phosphorylation was
preferentially inhibited in PDGF-bb-induced cells treated
with resveratrol. It is known that VSMC phenotype is
determined by changes in the balance of activation between
the Akt pathway, the ERK, and p38MAPK pathways.
Therefore, the Akt pathway plays a vital role in maintaining
the differentiated phenotype [29].
6 Oxidative Medicine and Cellular Longevity
0
5
10
15
20
25
30
35
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
D
ist
rib
ut
io
n 
of
 ce
ll 
nu
m
be
r
Circularity
(a)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
− + + +
− − 10 20
Ci
rc
ul
ar
ity
#
#
resveratrol
(𝜇M)
10ng/mL
PDGF-bb
∗
∗
#
(b)
0
2000
4000
6000
8000
10000
− + + +
− − 10 20resveratrol
(𝜇M)
10ng/mL
PDGF-bb
∗
##
C
el
l a
re
a (
𝜇
m
2
/c
el
l)
(c)
Figure 4: Morphology modulation by resveratrol in PDGF-bb-stimulated RAOSMCs. (a) The distribution of circularity ranged from 0 to 1,
for linear to circular, respectively. (—in serum free, —∙— in 10 ng/mL PDGF-bb, and ∙ ∙ ∙ ∙ ∙ in 10 ng/mL PDGF-bb with 20 𝜇M resveratrol).
(b)The average circularity ±SD was obtained from 100 single cells per each type. ∗𝑃 < 0.05 compared with nonstimulated control; #𝑃 < 0.05
compared with 10 ng/mL PDGF-bb-stimulated control. (c) The average area (𝜇m2/cell) ± SD was obtained from 100 single cells of each type.
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𝑃 < 0.05 compared with nonstimulated control; #𝑃 < 0.05 compared with 10 ng/mL PDGF-bb-stimulated control.
The phosphoinositol-Akt-mammalian target of the
rapamycin-p70S6 kinase (PIK/Akt/mTOR/p70S6K) pathway
regulates cell growth and cell differentiation in response to
nutrients, growth factors, and cytokines [30, 31]. Pharma-
cological inhibition with rapamycin was shown to induce
contractile morphology, SM2-MHC, and calponin, protein
reduction, and collagen synthesis in cultures of synthetic
phenotype VSMCs by regulation of the mTOR/p70 S6K1
pathway [30]. Previous studies have shown that mTOR acti-
vation induced SMCproliferation and required the activation
of the signaling cascade PI3K/PDK1/Akt, as assessed by the
effect of the PI3K inhibitors wortmannin and Ly294002,
which block PDK [10, 11, 32].Thus, resveratrol inhibited SMC
phenotypic modulation by changing the balance between the
Akt and MAPK pathways via hindering PDGF-bb-induced
Akt pathways, but not the ERK and p38MAPKpathways. Fur-
thermore, inhibition ofAkt/mTORpathways by resveratrol in
SMC affected not only DNA synthesis, but also expression of
phenotype-related proteins. Acute or chronic administration
of plant polyphenols in patients has been found to result
in the vasoprotective, antiangiogenic, antiatherogenic,
vasorelaxant, and antihypertensive effects [33]. Several
reports demonstrate resveratrol’s efficacy in inhibiting VSMC
proliferation [34, 35]. Furthermore, it has been shown that
resveratrol specifically blocks the PI3K/PDK1/Akt pathway,
thereby inhibiting oxLDL-induced SMC proliferation [14].
In this study, we focused on the effect of resveratrol on
phenotypic modulation of RAOSMCs following stimulation
with PDGF-bb. From a general point of view, resveratrol
exhibits various potentially inhibitory properties on dediffer-
entiation, including an antiproliferative effect and an ability
to modulate important growth signaling pathways.
5. Conclusion
In this study, we investigated the effect of resveratrol on
dedifferentiation of RAOSMCs induced byPDGF-bb. Resver-
atrol inhibited dedifferentiation, phenotypic alterations, and
proliferation rate stimulated by PDGF-bb in RAOSMC. In
conclusion, our results indicate that this effect was probably
mediated via a differential regulation of the balance between
Akt, 42/44MAPK, and p38MAPK pathway activations stim-
ulated by PDGF-bb at least in part for the effect of resveratrol.
This result suggests that resveratrol may be an inhibitor of the
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Figure 5: Continued.
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Figure 5: The effects of resveratrol on modulation of PDGF-bb-stimulated signaling pathways in RAOSMCs. RAOSMCs starved of serum
were stimulated with 10 ng/mL PDGF-bb and 100 𝜇M resveratrol for the indicated times (10m, 30m, 1 h, 2 h, and 4 h) and lysed. Lysates were
immunoblotted with antibodies. After densitometric quantification using the ImageJ program, data were expressed each as the mean ± SD
from three independent experiments. Black bar indicates expression by PDGF-bb stimulation. White bar indicates expression by PDGF-
bb stimulation with EGCG. (a) The expression of phospho-PDGFR-𝛽 in a time-dependent manner. The band intensities were normalized
to PDGFR-𝛽 expression. (b) The time-dependent expressions of phospho-MEK1/2 and phospho-p42/44MAPK. The band intensities were
normalized to MEK1/2 and p42/44MAPK expression. (c) The time-dependent expression of phospho-p38 MAPK.The band intensities were
normalized to p38 MAPK expression. (d) The time-dependent expression of phospho-Akt and phospho-mTOR. The band intensities were
normalized to Akt and mTOR expression.
phenotype modulation occurring in arterial stenosis and in
postangioplasty restenosis following vascular injury.
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